MA34946B1 - Nouvelles benzodioxolepipérazines - Google Patents
Nouvelles benzodioxolepipérazinesInfo
- Publication number
- MA34946B1 MA34946B1 MA36210A MA36210A MA34946B1 MA 34946 B1 MA34946 B1 MA 34946B1 MA 36210 A MA36210 A MA 36210A MA 36210 A MA36210 A MA 36210A MA 34946 B1 MA34946 B1 MA 34946B1
- Authority
- MA
- Morocco
- Prior art keywords
- benzodioxolepiperazines
- new
- formula
- present
- ht2a
- Prior art date
Links
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 abstract 1
- 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE DE NOUVEAUX MODULATEURS DOUBLES DES RÉCEPTEURS 5-HT2A ET D3 DE FORMULE (I) OÙ N, Y, R1, R2, R3 ET R4 SONT TELS QUE DÉCRITS DANS LA PRÉSENTE INVENTION, AINSI QUE LEURS SELS ET ESTERS DE QUALITÉ PHARMACEUTIQUE. EN OUTRE, LA PRÉSENTE INVENTION CONCERNE LA FABRICATION DES COMPOSÉS DE FORMULE (I), LES COMPOSITIONS PHARMACEUTIQUES LES INCLUANT ET LEUR UTILISATION COMME MÉDICAMENTS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11154780 | 2011-02-17 | ||
PCT/EP2012/052440 WO2012110470A1 (fr) | 2011-02-17 | 2012-02-14 | Nouvelles benzodioxolepipérazines |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34946B1 true MA34946B1 (fr) | 2014-03-01 |
Family
ID=45722618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36210A MA34946B1 (fr) | 2011-02-17 | 2012-02-14 | Nouvelles benzodioxolepipérazines |
Country Status (19)
Country | Link |
---|---|
US (1) | US8722683B2 (fr) |
EP (1) | EP2675798B1 (fr) |
JP (1) | JP2014505715A (fr) |
KR (1) | KR20140006953A (fr) |
CN (1) | CN103380122B (fr) |
AR (1) | AR085236A1 (fr) |
AU (1) | AU2012217150A1 (fr) |
BR (1) | BR112013020656A2 (fr) |
CA (1) | CA2823988A1 (fr) |
CO (1) | CO6761304A2 (fr) |
CR (1) | CR20130318A (fr) |
EA (1) | EA201391124A1 (fr) |
EC (1) | ECSP13012838A (fr) |
ES (1) | ES2546430T3 (fr) |
HK (1) | HK1189880A1 (fr) |
MA (1) | MA34946B1 (fr) |
MX (1) | MX2013008531A (fr) |
SG (1) | SG192819A1 (fr) |
WO (1) | WO2012110470A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106518841B (zh) * | 2015-09-15 | 2019-03-05 | 浙江京新药业股份有限公司 | 环己烷衍生物或其立体异构体或盐及其制备与应用 |
EP3495363B1 (fr) | 2016-07-28 | 2023-08-23 | Shionogi & Co., Ltd | Composés cycliques condensés contenant de l'azote ayant un effet antagoniste du récepteur de la dopamine d3 |
JPWO2019146739A1 (ja) | 2018-01-26 | 2021-01-07 | 塩野義製薬株式会社 | ドーパミンd3受容体拮抗作用を有する縮環化合物 |
WO2019146740A1 (fr) | 2018-01-26 | 2019-08-01 | 塩野義製薬株式会社 | Composé cyclique présentant un antagonisme au récepteur d3 de la dopamine |
WO2020156312A1 (fr) * | 2019-01-30 | 2020-08-06 | 江苏豪森药业集团有限公司 | Modulateur de dérivé polycyclique, son procédé de préparation et son application |
CN112239433B (zh) * | 2019-07-17 | 2024-05-14 | 北京盈科瑞创新药物研究有限公司 | 一种环己烷衍生物、制备方法及其应用 |
CN110372557B (zh) * | 2019-08-06 | 2021-05-18 | 上海勋和医药科技有限公司 | 环己烷胺类d3/d2受体部分激动剂 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3347381B2 (ja) * | 1993-01-27 | 2002-11-20 | 協和醗酵工業株式会社 | ペットフード |
WO1996039133A1 (fr) | 1995-06-06 | 1996-12-12 | Neurobiological Technologies, Inc. | Nouvelles 2-amino-3'-4'-methylene-dioxypropiophenones n-substituees |
EP1683790A1 (fr) * | 2005-01-24 | 2006-07-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Dérivés de 3,4-dihydro-2-naphtamide comme ligands selectifs de la dopamine D3 |
HUP0500170A3 (en) * | 2005-02-03 | 2007-11-28 | Richter Gedeon Nyrt | Piperazine derivatives, process for producing them and pharmaceutical compositions containing them |
CA2640807A1 (fr) | 2006-02-17 | 2007-08-23 | F. Hoffmann-La Roche Ag | Derives de benzoyle piperidine en tant que modulateurs 5ht2/d3 |
JP5087631B2 (ja) * | 2006-10-31 | 2012-12-05 | エフ.ホフマン−ラ ロシュ アーゲー | 5−ht2a及びd3受容体のデュアルモジュレーターのエーテル誘導体 |
ES2498673T3 (es) * | 2007-07-26 | 2014-09-25 | F. Hoffmann-La Roche Ag | Moduladores duales de los receptores 5-HT2a y D3 |
US7875610B2 (en) * | 2007-12-03 | 2011-01-25 | Richter Gedeon Nyrt. | Pyrimidinyl-piperazines useful as D3/D2 receptor ligands |
CA2735400A1 (fr) | 2008-09-22 | 2010-03-25 | F. Hoffmann-La Roche Ag | Modulateurs des recepteurs d3 et 5-ht2a derives de piperazine |
EP2334644A1 (fr) * | 2008-09-23 | 2011-06-22 | F. Hoffmann-La Roche AG | Dérivés de pyridinylpipérazine utiles en tant que modulateurs de récepteurs d3 de la dopamine |
US8586579B2 (en) * | 2010-06-21 | 2013-11-19 | Hoffmann-La Roche Inc. | Anellated pyridine compounds |
US8598357B2 (en) * | 2011-03-03 | 2013-12-03 | Hoffmann-La Roche Inc. | Benzodioxole piperidine compounds |
-
2012
- 2012-02-10 US US13/370,345 patent/US8722683B2/en not_active Expired - Fee Related
- 2012-02-14 BR BR112013020656A patent/BR112013020656A2/pt not_active IP Right Cessation
- 2012-02-14 CN CN201280009057.7A patent/CN103380122B/zh not_active Expired - Fee Related
- 2012-02-14 MX MX2013008531A patent/MX2013008531A/es active IP Right Grant
- 2012-02-14 MA MA36210A patent/MA34946B1/fr unknown
- 2012-02-14 CA CA2823988A patent/CA2823988A1/fr not_active Abandoned
- 2012-02-14 WO PCT/EP2012/052440 patent/WO2012110470A1/fr active Application Filing
- 2012-02-14 EA EA201391124A patent/EA201391124A1/ru unknown
- 2012-02-14 KR KR1020137024327A patent/KR20140006953A/ko not_active Application Discontinuation
- 2012-02-14 JP JP2013553896A patent/JP2014505715A/ja active Pending
- 2012-02-14 ES ES12705101.9T patent/ES2546430T3/es active Active
- 2012-02-14 EP EP12705101.9A patent/EP2675798B1/fr not_active Not-in-force
- 2012-02-14 AU AU2012217150A patent/AU2012217150A1/en not_active Abandoned
- 2012-02-14 SG SG2013062443A patent/SG192819A1/en unknown
- 2012-02-15 AR ARP120100497A patent/AR085236A1/es not_active Application Discontinuation
-
2013
- 2013-06-21 CO CO13148386A patent/CO6761304A2/es not_active Application Discontinuation
- 2013-06-25 CR CR20130318A patent/CR20130318A/es unknown
- 2013-08-16 EC ECSP13012838 patent/ECSP13012838A/es unknown
-
2014
- 2014-03-21 HK HK14102838.6A patent/HK1189880A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AR085236A1 (es) | 2013-09-18 |
MX2013008531A (es) | 2013-08-12 |
US8722683B2 (en) | 2014-05-13 |
ECSP13012838A (es) | 2013-09-30 |
EP2675798B1 (fr) | 2015-07-01 |
CR20130318A (es) | 2013-09-03 |
BR112013020656A2 (pt) | 2016-10-18 |
WO2012110470A1 (fr) | 2012-08-23 |
JP2014505715A (ja) | 2014-03-06 |
CN103380122A (zh) | 2013-10-30 |
ES2546430T3 (es) | 2015-09-23 |
US20130040948A1 (en) | 2013-02-14 |
CN103380122B (zh) | 2015-04-29 |
EA201391124A1 (ru) | 2014-02-28 |
HK1189880A1 (en) | 2014-06-20 |
SG192819A1 (en) | 2013-09-30 |
CO6761304A2 (es) | 2013-09-30 |
CA2823988A1 (fr) | 2012-08-23 |
KR20140006953A (ko) | 2014-01-16 |
AU2012217150A1 (en) | 2013-05-02 |
EP2675798A1 (fr) | 2013-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34946B1 (fr) | Nouvelles benzodioxolepipérazines | |
MA33939B1 (fr) | 5-alcynyl-pyrimidines | |
MA37886A1 (fr) | Nouvelles pyridinones bicycliques | |
MA34069B1 (fr) | Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a) | |
EA201171066A1 (ru) | Новые замещенные производные бензоксазола, бензимидазола, оксазолопиридина и имидазопиридина в качестве модуляторов гамма-секретазы | |
MA37400B1 (fr) | Composés hétérocyclyle en tant qu'inhibiteurs de mek | |
TN2012000543A1 (en) | Hexafluoroisopropyl carbamate derivatives, their preparation and their therapeutic application | |
EA201290654A1 (ru) | Новые замещенные триазольные производные как модуляторы гамма-секретазы | |
UA111770C2 (uk) | Інгібітори бромдомену | |
BR112014000713A2 (pt) | derivados de indol substituído como moduladores de gama secretase | |
EA201001205A1 (ru) | Соединения, содержащие циклобутоксигруппу | |
EA201170772A1 (ru) | Органические соединения | |
UY32259A (es) | Nuevos compuestos de hidroxiareno, preparados farmaceuticos que los contienen y aplicaciones | |
EA201792046A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
MA35749B1 (fr) | Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc | |
EA201270216A1 (ru) | Фармацевтический состав | |
EA201390198A1 (ru) | Гетероциклическое соединение | |
EA201490471A1 (ru) | Пиридазиноновые соединения и их применение в качестве ингибиторов daao | |
EA201201050A1 (ru) | Пиразолы в качестве антагонистов crth2 | |
EA201491002A1 (ru) | Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2 | |
CR20130239A (es) | Compuestos de triazolopiridina | |
EA201190320A1 (ru) | Гетероциклические сульфонамиды, их применения и фармацевтические композиции | |
MA33948B1 (fr) | Dérivés d'acide 3-hétéroaroylamino-propionique substitues par oxygène et leur utilisation en tant qu'agents pharmaceutiques. | |
EA201290229A1 (ru) | Производные спиролактама и их применение | |
MX2013005966A (es) | Nuevos compuestos de benzofurano. |